OptimizeRx is a digital health marketing technology company that connects pharmaceutical and life sciences manufacturers with healthcare providers (HCPs) and patients. OptimizeRx operates two core channels: an HCP point-of-care network embedded within EHR and ePrescribing platforms used by over two million physicians, and a direct-to-consumer (DTC) channel acquired through the 2023 purchase of Medicx Health. The HCP channel delivers brand messaging, copay offers, and drug availability alerts directly inside clinical workflows at the moment a physician is writing a prescription. The DTC channel uses OptimizeRx's patented Micro-Neighborhood Targeting (MNT) solution, which scores geographies by concentration of brand-eligible patients using de-identified claims data, then activates those geographies across connected TV, programmatic display, social media, and other consumer media channels. OptimizeRx sells exclusively to pharma and life sciences manufacturers and their agency partners. Revenue comes from campaign-based program delivery, managed services, and a growing subscription component tied to its Dynamic Audience Activation Platform (DAAP), which uses AI to identify which physicians are likely to see brand-eligible patients in a near-term window. OptimizeRx is converting DAAP's data fees from transactional to annual subscriptions, which carry higher margins since OptimizeRx owns the underlying IP. The company pursues a land-and-expand sales motion, starting with pilots and scaling across brands, disease states, and channels. Revenue is heavily back-half weighted, with Q4 historically representing the largest quarter due to pharma budget cycles.